AstraZeneca to switch to direct US listing, retain UK base
PositiveFinancial Markets

AstraZeneca has announced its decision to switch to a direct listing in the US while maintaining its base in the UK. This move is significant as it reflects the company's commitment to expanding its presence in the American market, which could lead to increased investment and growth opportunities. By opting for a direct listing, AstraZeneca aims to enhance its visibility and accessibility to investors, potentially boosting its stock performance and overall market position.
— Curated by the World Pulse Now AI Editorial System